Acadia Pharmaceuticals (ACAD) Cash & Current Investments (2010 - 2026)

Acadia Pharmaceuticals' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $851.5 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 24.92% year-over-year to $851.5 million in Q1 2026; TTM through Mar 2026 was $851.5 million, a 24.92% increase from a year earlier, with the FY2025 full-year figure at $819.7 million, up 8.43% from the prior year.
• Cash & Current Investments grew to $851.5 million in Q1 2026 per ACAD's latest filing, from $819.7 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $851.5 million in Q1 2026 and bottomed at $345.9 million in Q3 2023.
• The 5-year median for Cash & Current Investments is $470.5 million (2024), against an average of $562.0 million.
• Across the five-year window, Cash & Current Investments declined 22.81% in 2022 and jumped 72.26% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $416.8 million in 2022, then rose by 5.29% to $438.9 million in 2023, then soared by 72.26% to $756.0 million in 2024, then rose by 8.43% to $819.7 million in 2025, then gained by 3.88% to $851.5 million in 2026.
• Per Business Quant, the three latest ACAD Cash & Current Investments figures stand at $851.5 million (Q1 2026), $819.7 million (Q4 2025), and $847.0 million (Q3 2025).